Personal tools

You are here: Home / News & Events / BioEngenuity Keynotes 6th March 2017

BioEngenuity Keynotes 6th March 2017

Join The Institute of Biomedical Engineering for the second BioEngenuity Keynote followed by a networking lunch and interactive poster session.
When Mar 06, 2017
from 11:00 AM to 02:00 PM
Where Richard Doll Lecture Theatre
Contact Name
Contact Phone 01865 617706
Add event to calendar vCal

11:00-11:30     Prof. Maarten De Vos, IBME

  “Mind-reading” out of the lab: where are the limits?

11:30-12:00   Prof. Robin Cleveland, IBME

  “Shocking heads: how sound can damage and heal the brain”

12:00-13:00 Kristoffer Famm, PhD, President, Galvani Bioelectronics

"Bioelectronic medicine co-created  – why precision neuromodulation holds the promise to revolutionise treatment of chronic disease, and where we stand in bringing that promise to patients"

 Abstract: Electrical and molecular signalling constitute main axes of control in biology. Peripheral nerves conduct electrical impulses to and from organs, regulating a wide range of physiological processes, from muscle contraction to hormone secretion and biochemical reactions.

These same processes gone awry are at the centre of many chronic diseases such as arthritis, diabetes and asthma. Bioelectronic medicine is a new field that aims to treat disease with miniaturised, implantable devices that, with precision, modulate such electrical impulses. Bioelectronics has the potential to be a major treatment modality alongside small and large molecules as chronic diseases increase their impact around the world.

Galvani Bioelectronics was formed at end of 2016 by combining the efforts of GlaxoSmithKline and Verily (formerly Google Life Sciences), creating a powerful R&D engine to bring this vision to reality. This lecture by the company’s president will outline the therapeutic potential currently being unfolded by a global network of academic and industry research partners, describe how biology needs and technology solutions are coming together into a new generation of implantable devices, and discuss the research challenges and opportunities that lie ahead.



Kris Famm is president of Galvani Bioelectronics, being overall responsible for the company’s path to and delivery of bioelectronic medicines to patients. Before his appointment to lead Galvani Bioelectronics, he was VP and head of Bioelectronics R&D at GSK, which he launched in 2013. There he managed the unit’s extensive research towards establishing the treatment potential, disease reach and technology requirements for modulating signals in visceral, peripheral nerves, working together with a global network of partners across academia and industry.

During his time at GSK he also headed up the R&D Strategy Group and the Protein Degradation Discovery Performance Unit.

Kris obtained his PhD in Molecular Biology at University of Cambridge, following an MSc in Chemical Engineering at Lund University, Sweden. Before joining GSK in 2009, he worked as a management consultant at McKinsey & Co

More information about this event…